HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...
KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRNewswire/ -- Hyatt Regency Kuala Lumpur at KL Midtown has been honoured with a Commendation (Hospitality) at the Malaysian...
Renewed collaboration will deliver exclusive market intelligence, thought leadership, and actionable growth opportunities to help the global automotive aftermarket navigate its next era of...
At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance,...
Renowned economist to lead global initiatives addressing industrial policy, economic statecraft and non-market strategy SAN CLARA, Calif., Aug. 4, 2026 /PRNewswire/ -- Frost...
